

Emergence of SARS-CoV-2 Omicron Variant JN.1 in Tamil Nadu, India - Clinical Characteristics and Novel Mutations

Sivaprakasam T. Selvavinayagam^{1†}, Sathish Sankar^{2†}, Yean K. Yong^{3,4†}, Amudhan Murugesan⁵, Suvaiyaran Suvaitenamudhan^{6†}, Kannan Hemashree¹, Manivannan Rajeshkumar¹, Anandhazhvar Kumaresan¹, Ramendra P. Pandey⁷, Saravanan Shanmugam⁸, Parthiban Arthydevi¹, Masilamani S. Kumar¹, Natarajan Gopalan⁹, Meganathan Kannan¹⁰, Narayanaiah Cheedarla¹¹, Hong Y. Tan¹², Ying Zhang^{13,4}, Marie Larsson¹⁴, Pachamuthu Balakrishnan⁸, Vijayakumar Velu¹¹, Siddappa N. Byrareddy¹⁵, Esaki M. Shankar^{16*}, and Sivados Raju^{1*}

¹State Public Health Laboratory, Directorate of Public Health and Preventive Medicine, DMS Campus, Teynampet, Chennai 600 006, Tamil Nadu, India.

²Department of Microbiology, Centre for Infectious Diseases, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai 600 077, Tamil Nadu, India.

³Laboratory Center, Xiamen University Malaysia, 43900 Sepang, Selangor, Malaysia.

⁴*Kelip* *kelip!* Center of Excellence for Light Enabling Technologies, Xiamen University Sepang, Selangor, Malaysia

⁵Department of Microbiology, Government Theni Medical College and Hospital, Theni-625 512, India.

⁶School of Biomedical Sciences, Sri Balaji Vidyapeeth, (Deemed to be University), Pondicherry 607 402, India.

⁷School of Health Sciences and Technology, UPES, Dehradun 248007, Uttarakhand, India.

⁸Center for Infectious Diseases, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 602105, Tamil Nadu, India.

⁹Department of Epidemiology and Public Health, Central University of Tamil Nadu, Thiruvarur 610 005, India.

¹⁰Blood and Vascular Biology, Department of Biotechnology, Central University of Tamil Nadu, Thiruvarur 610 005, India.

¹¹Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Division of Microbiology and Immunology, Emory National Primate Research Center, Emory Vaccine Center, Atlanta, GA, 30329, USA.

¹²School of Traditional Chinese Medicine, Xiamen University Malaysia, Sepang, Selangor, Malaysia.

¹³Chemical Engineering, Xiamen University Malaysia, Sepang, Malaysia.

¹⁴Division of Molecular Medicine and Virology, Department of Biomedical and Clinical Sciences, Linköping University, 58 183 Linköping, Sweden.

¹⁵Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68131, USA.

¹⁶Infection and Inflammation, Department of Biotechnology, Central University of Tamil Nadu, Thiruvarur 610 005, India.

[†]These authors contributed equally

Corresponding authors

***Sivados Raju**, State Public Health Laboratory, Directorate of Public Health and Preventive Medicine, Teynampet, Chennai, India. Email: sivraju@gmail.com

***Esaki M Shankar**, Infection and Inflammation, Department of Biotechnology, Central University of Tamil Nadu, Thiruvarur, India. Email: shankarem@cutn.ac.in

52 **Keywords:** Omicron variant, JN.1 variant, SARS-CoV-2, Whole genome sequencing,
53 mutation, Spike protein

54

55 **Running title:** Emergence of JN.1 SARS CoV-2 variant in Tamil Nadu.

56

57 **ABSTRACT**

58 In December 2023, we observed a notable shift in the COVID-19 landscape, when the JN.1
59 emerged as a predominant SARS-CoV-2 variant with a 95% incidence. We characterized the
60 clinical profile, and genetic changes in JN.1, an emerging SARS-CoV-2 variant of interest.
61 Whole genome sequencing was performed on SARS-CoV-2 positive samples, followed by
62 sequence analysis. Mutations within the spike protein sequences were analyzed and compared
63 with the previous lineages and sublineages of SARS-CoV-2, to identify the potential impact of
64 these unique mutations on protein structure and possible functionality. Several unique and
65 dynamic mutations were identified herein. Our data provides key insights into the emergence
66 of newer variants of SARS-CoV-2 in our region and highlights the need for robust and
67 sustained genomic surveillance of SARS-CoV-2.

68

69 **INTRODUCTION**

70 The emergence of the novel coronavirus, SARS-CoV-2, in December 2019, has prompted an
71 urgent need to investigate the evolutionary dynamics of the virus, globally. Since their initial
72 identification, these viruses have constantly undergone mutations, leading to the emergence of
73 several ‘variants of concern’ due to evolutionary dynamics [1]. Viral mutations inherent to the
74 replication process have led to the development of diverse variants characterized by distinct
75 transmissibility and resistance profiles. Since the SARS-CoV-2 pandemic, the virus emerged
76 with five variants of concern (Alpha, Beta, Gamma, Delta, Omicron). Among these, the
77 Omicron variant (B.1.1.529) exhibited more than 50 characteristic mutations in different
78 motifs of the spike protein [2]. The virus along with its subsequent concerning sublineages and
79 variants, evolved with enhanced transmissibility, infectivity and immune evasion mechanism.
80 Notable subvariants, including BA.2, BA.5, and XBB were of particular interest due to their
81 rapid spread across the globe and evasion from neutralizing and monoclonal antibodies [3, 4].
82 Specific genetic changes within the virus have conferred selective advantages, augmenting its
83 ability to propagate and evade host immune responses, thereby presenting formidable
84 challenges to containment and treatment strategies [5].

85

86 These dynamic and ever-evolving viral mutations underscore the imperative necessity for
87 consistent monitoring and use of adaptive methodologies, such as whole-genome sequencing.
88 The ongoing surveillance of viral genomes facilitates the prompt identification of emerging
89 variants, playing a pivotal role in devising public health measures and targeted interventions.
90 Furthermore, a profound understanding of the genetic alterations steering the viral behaviour
91 becomes instrumental in developing effective treatments and vaccines, ensuring a resilient
92 response to the constantly evolving viral threats [6]. The impact of mutations on the protein
93 function is now studied through *in silico* methods [7, 8]. The difference in protein structures
94 induced by mutations resulting in different lineages during the viral evolutionary process [9].
95 Here, we surveyed the population for SARS-CoV-2 Omicron subvariant JN.1 between
96 November and December 2023 as a part of the state’s public health genomic surveillance
97 investigation, an ongoing programme of the Directorate of Public Health and Preventive
98 Medicine, Chennai, India since September 2021.

99

100 **MATERIALS AND METHODS**

101

102 **Study design**

103 The study was part of the SARS-CoV-2 genomic surveillance by the State Public Health
104 Laboratory (SPHL), Directorate of Public Health and Preventive Medicine, Chennai, India.
105 COVID-19 diagnosis was based on clinical and laboratory tests using nasopharyngeal and
106 oropharyngeal swabs as per the guidelines of the Centers for Disease Control and Prevention
107 (CDC), Atlanta, USA. Written informed consent was obtained before sampling. Patients'
108 demographic details and clinical presentations were collected, including underlying
109 comorbidities, vaccination history, disease progression, and outcome. Of the 471 COVID-19-
110 positive samples reported in Tamil Nadu between November and December 2023, 92 samples
111 with a cycle threshold (Ct) value of <25 were chosen for whole genome sequencing. RNA
112 extraction was carried out using MagMAX Viral/Pathogen II Nucleic Acid isolation kit
113 (Thermo Fisher Scientific, USA) and tested for SARS-CoV-2 using TaqPath COVID-19 RT-
114 PCR kit (Thermo Fisher Scientific, USA) according to the manufacturer's instructions. The
115 RNA elutes were stored at -80°C until further testing.

116

117 **Ethics approval**

118 The study was approved (EC No. 03092021) by the Institutional Ethics Committee of the
119 Madras Medical College and Hospital, Chennai. The clinical classification was based on the
120 Clinical Guidance for Management of Adult COVID-19 Patients by the Ministry of Health
121 and Family Welfare, Government of India (January 2022).

122

123 **Whole genome sequencing**

124 Complementary DNA (cDNA) was prepared from RNA elutes using the SuperScript VILO
125 cDNA Synthesis kit (Invitrogen, Thermo Fisher Scientific, USA) as per the manufacturer's
126 instructions. Among 471 SARS-CoV-2 positive samples reported during the study period,
127 whole genome sequencing was carried out on 66 of 92 samples with cycle threshold (Ct)
128 values <25 as per the World Health Organization (WHO) criterion. Ion AmpliSeq library kit
129 (ThermoFisher Scientific, Waltham, USA) was used for the library preparation, and the final
130 library was adjusted to a final concentration of 75 pM using the low TE buffer and loaded onto
131 Ion Chef instrument for emulsion PCR, enrichment, and subsequent placement onto an Ion 540
132 chip. Next-generation sequencing (NGS) was conducted using the Ion Torrent NGS System
133 using the Ion GenStudio S5 Plus System (Thermo Fisher Scientific, Waltham, USA). Data
134 analysis was performed using Torrent Suite™ software ver.5.18.1. The consensus sequence
135 was analysed using IRMA report ver.1.3.0.2. Annotation was performed using the SnpEff
136 program. The reads were aligned to the *Wuhan Hu-1* strain as a reference genome (NCBI ID:
137 NC_045512.2).

138

139 **Phylogenetic and evolutionary analysis of spike protein**

140 The phylogenetic analysis of SARS-CoV-2 was carried out to identify the mutations and
141 relatedness of the JN.1 variant with other SARS-CoV-2 variants using the Nextclade online
142 software v.3.2.0. (<https://clades.nextstrain.org/>) [10]. The nucleotide sequences coding for
143 spike protein from the datasets available in the Nextclade as reference sequences and reference
144 genomes of SARS-CoV-2 variants from the NCBI database were selected and used to detect
145 the mutations. The Nextclade reference datasets, GenBank accession numbers and the list of
146 mutations are provided in **Supplementary Table 1**. The mutations that were unique to the
147 study sequences are called 'unique mutations', whereas those observed in the global JN.1
148 strains are called 'universal mutations'. The dynamic mutations characteristically appearing
149 and reappearing in the subsequent variants of SARS-CoV-2 are called 'dynamic mutations'.
150 Other mutations that were observed with no characteristic pattern were denoted as 'random
151 mutations'.

152

153 **Mutations and superimposition of 3D spike protein structure**

154 Mutations unique to the study sequences were compared with the *Wuhan Hu-1* and other
155 major lineages and sublineages, including XBB and the other reported JN.1 sequences.
156 Mutations were created in the 3D protein structure using PyMol Molecular Graphics System.
157 Using the mutagenesis function and best rotamer based on the frequency of its occurrence and
158 clashes with neighbouring amino acids, the mutation was selected and created. A 3D structure
159 model was created with JN.1 specific mutations using *Wuhan-Hu-1* as the reference (model
160 A), and a model with unique mutations was identified in our study using the reference JN.1
161 (model B). The above models were superimposed to identify any structural variations due to
162 these mutations. A 3D protein model for the *Wuhan Hu-1* spike protein was built using Swiss-
163 model protein structure homology modelling, upon which mutations were created using the
164 Pymol program. The quality of the developed model was analyzed using SAVES and
165 Procheck online server programs. The root mean square deviation (RMSD) values were used
166 to assess the mutation-induced structural effects on the protein, where a score of 0 indicates
167 identical structures and a high value indicates higher dissimilarity [11, 12].
168

169 RESULTS

170 Clinico-demographic characteristics of the JN.1 cohort

171 The ongoing SARS-CoV-2 genomic surveillance activities at SPHL have identified the
172 dramatic emergence of the JN.1 variant of omicron by replacing the XBB variant between
173 November and December 2023 (Fig 1A). The age of the JN.1 positive patients ranged from 1
174 to 89 years, with the median age during the study period being 51 (Fig 1B) and with an equal
175 proportion of male-to-female ratio (Fig 1C). More than 50% of the JN.1 patients had diabetes
176 mellitus, followed by 21% of the cases with hypertension, and 10 % of the cases had both
177 diabetes mellitus and hypertension (Fig 1D). About 87% of the patients were presenting fever,
178 cold, cough and sore throat (Fig 1E & I). On analysing the vaccination status of the JN.1
179 positive patient, 93.5% had received COVID-19 vaccinations, indicating a high proportion of
180 vaccine breakthrough infections (Fig 1F). Among the vaccinated, 98% had received two or
181 more doses of COVID-19 vaccines (Fig 1G). About 45% of the JN.1 patients were
182 hospitalized, of which 20% had severe illnesses requiring oxygen support and ICU care with
183 ventilator support. However, no deaths were recorded (Fig 1H). Among the different
184 symptoms presented by the patients, fever was the most common presentation (69%) and was
185 predominant among the 10-20 years (86%) and 80-90 years (80%) of age. The other common
186 symptoms found were cough (55%) which was predominant in older age groups, rhinorrhea
187 (20%) in younger age groups and sore throat (predominant in 20-40 years (36%) and 60-80
188 years (32%) age groups. Breathlessness (6%) and myalgia (1.8%) were less prevalent and were
189 mostly seen in older age groups only (Fig 1I).

190

191 Mutational analysis of spike protein

192 The S gene sequences of the 66 JN.1 study strains were analysed with different reference
193 genomes and revealed several unique mutations in the different domains of the S protein
194 including the receptor binding domain (RBD), signal peptide (SP) and N-terminal domain
195 (NTD) (Fig 2 and Table 1).

196

197 Comparison of spike protein sequences of JN.1 with *Wuhan-Hu-1*

198 On comparing our JN.1 isolates with the reference sequence of the *Wuhan-Hu-1* strain, we
199 have identified 22 unique mutations and 3 dynamic mutations. Of the unique mutations, the
200 majority of them occurred in NTD (n=16), followed by Heptad repeat (HR1/2) (n=3) and spike
201 subdomain (SD) (n=2), whereas RBD showed one mutation (V503A). Among the dynamic
202 mutations, two are seen in NTD (P85K and V90Y) and one in the signal domain (P681H).
203 Also, JN.1 showed six universal mutations (three in NTD, two in RBD-N440K and N501Y
204 and one in SD- D614G). This also encompasses some universal mutations, such as G142D,

205 which have been reported in several countries [13, 14]. Upon analysis of random mutations,
206 we found that JN.1 variants showed 40 mutations across the spike protein when compared to
207 *Wuhan-Hu-1* with a maximum number of mutations in RBD (23) followed by NTD (12)
208 (**Table 2** and **Fig 2A**).

209

210 **Comparison of spike protein sequences of JN.1 with BA.2**

211 Similarly, the results from the comparison of JN.1 with the BA.2 variant show unique
212 mutations, including V83F, L84K, P85L, F86L, N87I, D88V, V90L, Y170E, Q218L, and
213 T307R and dynamic mutations such as P85L, V90Y in the NTD domain and the following
214 unique mutations T333R, F456L, Q506P, and P507T found within the RBD domain. There
215 was no occurrence of universal mutations within any of the domains. This shows the amino
216 acid change compared to BA.2 were identified individually (**Table 3** and **Fig 2B**). We also
217 found a total of 34 random mutations when comparing JN.1 and BA.2 with 10 mutations in
218 NTD and 18 in RBD. The fusion peptide (FP) domain showed a mutation – H681R.

219

220 **Comparison of spike protein sequences of JN.1 with XBB**

221 Likewise, the comparison of JN.1 with the XBB variant showed no traces of universal
222 mutations and was found to have unique, dynamic, and random mutations. The unique
223 mutations in the NTD domain include A83V, L84K, P85K, F86L, N87I, D88V, V90L, F92V,
224 Y170E, and Q218L followed had two dynamic mutations (A83F and, V90Y). In the RBD
225 domain, unique mutations, including N331K, T333R, N334S, T346R, F456L, Q507P, and
226 P507T and dynamic mutation-T346I were identified. The other unique mutations, T315V,
227 S316C and F318I, were spotted in the intermediary region between NTD and RBD domains
228 (**Table 4** and Figure 2C). Our study shows 33 random mutations (13 in NTD, 14 in RBD, three
229 in SD1/2, two in HR1-2 and one in the FP).

230

231 **Evolutionary mutation patterns in spike protein sequences**

232 Furthermore, the evolutionary relatedness of JN.1 is presented in a phylogenetic tree that
233 depicts the hierarchy of the different lineages of the selected strain and the position of the JN.1
234 lineage in the tree. The JN.1 lineage showed an extended branch length in both rooted and
235 unrooted trees (**Fig 3**).

236

237 **Mutational and conformational changes in spike protein**

238 When our study sequences were compared with the reference genomes of different variants, 19
239 mutations were observed in our strains and previously reported JN.1 variants (but not seen in
240 other lineages). This indicated that the mutations were unique to the JN.1 variant. The list of
241 mutations and the specific motifs is given in **Table 5**, and the frequency of these mutations is
242 given in **Supplementary Table 1**. The other 24 mutations that were observed in a few
243 lineages/sub-lineages but not found in our 66 sequences were identified and listed in **Table 6**.

244

245 Intrigued by these mutations, we next elucidated the resulting protein structural changes with
246 the reference protein sequences. The 19 JN.1-specific mutations were created in the model and
247 superimposed with the reference protein. The superimposed structure showed an RMSD value
248 of 0.071Å (**Fig 4A**). The 17 study-specific mutations were created and superimposed with the
249 same model, which showed an RMSD value of 0.081Å (**Fig 4B**).

250

251 **DISCUSSION**

252 Here, the study describes the detection of SARS-CoV-2 Omicron subvariant JN.1 during
253 November and December-2023, as a part of the state public health genomic surveillance
254 activity which has been happening since September 2021. In our recent study, we showed the
255 mutational patterns of Omicron variants and the emergence of the XBB as a dominant variant

256 in January 2023 replacing BA.2 which continued till October 2023 [15, 16]. In September
257 2023, JN.1 was first identified in the United States [17] followingly many countries like
258 Canada, France, Singapore and the United Kingdom reported the emergence of JN.1 [18–21].
259 In India, the JN.1 variant was first identified on 6th October 2023. In Tamil Nadu, the first
260 case of JN.1 was reported on 27 December 2023, subsequently since then, JN.1 replaced the
261 XBB variant and was the most predominant SARS-CoV-2 variant in the state of Tamil Nadu,
262 India.

263

264 Along with the L455S, a hallmark FLip mutation of JN.1 in the spike protein, the present study
265 identified mutations in different domains of the protein, particularly in the NTD, RBD, SD1/2
266 and HR1/2 domains. Furthermore, the study identified several mutations when compared to
267 Wuhan-Hu-1, BA.2 and XBB. This indicates the adaptive evolutionary trends of the virus
268 possibly due to reduced neutralizing antibody responses [22, 23].

269

270 Since the emergence of JN.1 in August 2023 as a descendant of the BA.2.86 lineage, it drew
271 much attention due to mutation-induced interference in viral binding to angiotensin-binding
272 enzyme (ACE2) receptors [24, 25]. A significant rise in numbers of JN.1 variant, post
273 vaccinations indicates breakthrough infections with enhanced capacity of immune evasion
274 [26]. The predecessor XBB variant had 82% of immune evasiveness among the vaccinated
275 individuals [15], whereas the current JN.1 variant by acquiring several mutations led to
276 structural changes in the spike protein, conferring 95% of immune evasiveness [27]. This
277 warranted a detailed investigation on other additional mutations that JN.1 harboured
278 subsequently from its predecessors [28]. The present study analyzed the mutational dynamics
279 of the virus it inherited across the lineages and sublineages. Though the study does not
280 represent the true prevalence of the JN.1 in India, the widespread distribution of this variant in
281 the community warrants nationwide genomic surveillance of SARS-CoV-2 under the
282 INSACOG network.

283

284 Although viruses are constantly known to evolve due to genetic diversity and evolutionary
285 selection pressure, the clinical and immunological outcomes are always unpredictable. It is
286 therefore important to carry out continuous surveillance on SARS-CoV-2 variants and their
287 mutational analysis [29]. The mutational pattern leads to virus evolution resulting in the
288 emergence of variants with enhanced transmissibility, severity and immune evasion [30]. The
289 disappearance and re-appearance of certain mutations (dynamic mutations), in the course of
290 virus evolution with any possible clinical relevance is generally overlooked in evolutionary
291 studies. The present study takes cognizance of such dynamic patterns during virus evolution.
292 The analysis revealed dynamic mutations such as P85L to P85K, V90L to V90Y in the NTD
293 domain and P681R to P681H in the intermediate region between SD1/2 and FP. These
294 dynamic mutations were identified by comparing JN.1 with the *Wuhan-Hu-1*, BA.2 and XBB.
295 The mutational spectrum in the NTD domain of the spike protein has been an important
296 mechanism in driving antigenic variation and host adaptation [31]. Studies indicate that potent
297 neutralizing antibodies to NTD interact with residues F140S, G142D, Y145D, K150E, W152R
298 and R158S [32]. The study also showed that antibodies against both RBD and NTD could
299 efficiently neutralize SARS-CoV-2, limiting the emergence of neutralization-escape mutants.

300

301 Our study indicated universal mutation-G142D and common mutations-Q146H and R158G
302 identified in JN.1 variants in line with other studies [32, 33]. These findings further augment
303 the emergence of vaccine-escape mutants. Similarly, by comparing the JN.1 with XBB, we
304 show two dynamic mutations - A83V to A83F, V90L to V90Y in the NTD domain and T346R
305 to T346I in the RBD domain. This indicates that these mutations would possibly contribute to
306 the ongoing evolution of viral lineages, and their overall fitness and adaptability [34] Our

307 study identified a dynamic mutation P85K that has gradually evolved from the *Wuhan-Hu-1*
308 and BA.2 strain and reshaped into a unique mutation in comparison with XBB [15]. This
309 indicates the genetic drift within the SARS-CoV-2 infection particularly in the JN.1 variant.
310 These results were further supported by the phylogenetic tree where the JN.1 lineage showed
311 an increased branch length demonstrating both the evolutionary divergence and its
312 relationships with the other lineages of SARS-CoV-2 [35].

313

314 The impact of unique mutations identified in the spike protein of the study strains on its
315 structure was analyzed by superimposing the mutant model with the wild-type model. The
316 structural alignment between the two models was analyzed with the equivalent backbone
317 atoms. Every single mutation causes concomitant changes in protein folding, conformation,
318 physiochemical properties and *in situ* function [36]. The conformational changes upon
319 superimposition are analyzed with RMSD as a measurement. The predicted structural
320 modifications on ab initio protein models are a known limitation on the robustness yet
321 considered to be the best approach for comprehensive analysis of variants [7]. Protein function
322 predictions are now studied increasingly through computational methods as the curated protein
323 structures, along with experimentally determined host-pathogen protein interactions [8]. In the
324 present study, as anticipated, the superimposed structure showed only a slight deviation
325 ($<0.1\text{\AA}$) compared to the reference strains. Nevertheless, these mutations may be the prelude
326 for further mutations in the course of the evolution of the new sub-lineage. Therefore,
327 monitoring the periodical changes in the virus dynamics is important [37]. Through the
328 combination of high-throughput sequencing technologies with phylogenetic analysis, it is
329 possible to assess parallel patterns of evolution driving significant phenotypic shifts. These
330 methods offer a framework to measure and predict future evolutionary occurrences [38].

331

332 The present study identified 19 unique mutations among the study sequences. The majority of
333 the mutations occurred in the NTD and RBD domains followed by the HR1/2 region. The
334 mutations and the following structural changes in the NTD have been implicated in reduced
335 epitope recognition ensuing immune viral escape. The mutations of the RBD domain have
336 been implicated significantly with infectability, transmissibility, and antibody resistance. Spike
337 proteins are known to accumulate multiple mutations upon evolution, subsequently ranking up
338 the virion spike density and infectivity. The present study identified novel mutations of the
339 JN.1 variant, possibly contributing to high transmissibility and immune resistance. In addition,
340 the structural conformation analysis by superimposing them with reference protein structure
341 indicated structural divergence. The considerable deviations measured in conventional RMSD
342 could have been studied further to elucidate its functional variability. Our study also identified
343 24 mutations that were present in previous lineages but lost in the JN.1 variant, indicating the
344 dynamicity of such mutations. These dynamic mutations might play a substantial role in the
345 viral evolution and pathogenicity mechanism and are to be studied.

346

347 **CONCLUSIONS**

348 Recognizing the significance of mutations is crucial for modifying public health strategies and
349 therapeutic interventions. This study aimed to characterize the clinical profiling and genetic
350 modifications of the JN.1 variant to the previous variants of SARS-CoV-2, including the wild
351 type *Wuhan-Hu-1*, BA.2, and XBB. The study showed that the prevalent mutations in JN.1
352 may be responsible for their immune evasive properties, and acknowledged that the genetic
353 landscape of SARS-CoV-2 is inconstant and this capability to identify and respond to
354 alterations in the genetic composition of the virus is vital for effective pandemic governance.

355

356 **Author contributions**

357 Sivaprakasam T. Selvavinayagam, Masilamani Senthilkumar, Yean K. Yong, Suvaiyaran
358 Suvaithenamudhan, Amudhan Murugesan, Marie Larsson, Pachamuthu Balakrishnan,
359 Siddappa N. Byrareddy, Vijayakumar Velu, Esaki M. Shankar, and Sivados Raju designed
360 the study and were responsible for conceptualization and data curation. Sivaprakasam T.
361 Selvavinayagam, Narayanaiah Cheedarla, Kannan Hemashree, Sathish Sankar, Yean K. Yong,
362 Hong Y. Tan, Ying Zhang, Parthiban Arthydevi, Ramendra P. Pandey, Manivannan
363 Rajeshkumar, Anandhazhvar Kumaresan, Natarajan Gopalan, Meganathan Kannan, Marie
364 Larsson, Saravanan Shanmugam, Vijayakumar Velu, Pachamuthu Balakrishnan, Esaki
365 M.Shankar, and Sivados Raju conducted the analysis, and were responsible for methodology,
366 formal analysis, validation, and visualization. Sivaprakasam T. Selvavinayagam, Yean K.
367 Yong, Marie Larsson, Vijayakumar Velu, Esaki M. Shankar, and Sivados Raju wrote the first
368 draft of the manuscript. All authors provided critical inputs and approved the final version of
369 the manuscript for publication.

370

371 **Conflicts of interest**

372 There are no conflicts of interest to disclose by any authors.

373

374 **Funding information**

375 S.T.S. and S.R. are funded by the National Health Mission, Tamil Nadu
376 (680/NGS/NHMTNMSC/ENGG/2021) for the Directorate of Public Health and Preventive
377 Medicine, WGS facility. M.L. is supported by grants through AI52731, the Swedish Research
378 Council, the Swedish, Physicians against AIDS Research Foundation, the Swedish
379 International Development Cooperation Agency, SIDASARC, VINNMER for Vinnova,
380 Linköping University Hospital Research Fund, CALF, and the Swedish Society of Medicine.
381 V.V. is supported by the Office of Research Infrastructure Programs (ORIP/NIH) base grant
382 P51 OD011132 to ENPRC. A.M. is supported by Grant No. 12020/04/2018-HR, Department
383 of Health Research, Government of India. The funders of the study had no role in the study
384 design, data collection, data analysis, data interpretation, or writing of the report. The authors
385 thank the Indian SARS CoV-2 Genomics Consortium (INSACOG), Department of
386 Biotechnology, Ministry of Science and Technology, Government of India for their approval
387 and inclusion of the State Public Health Laboratory (SPHL) as INSAGOG Genomic
388 Sequencing Laboratory (IGSL) vide File No: RAD-22017/28/2020-KGDDBT-Part (6)
389 Dated 29th December 2021.

390

391 **Ethical approval statement**

392 The study was approved by the Institutional Ethical Committee of Madras Medical College
393 and Hospital, Chennai (EC No. 03092021).

394

395 **Patient consent statement**

396 Patient written informed consent was obtained.

397

398 **Acknowledgements**

399 S.T.S. and S.R. are funded by the National Health Mission, Tamil Nadu
400 (680/NGS/NHMTNMSC/ENGG/2021) for the Directorate of Public Health and Preventive
401 Medicine, WGS facility. M.L. is supported by grants through AI52731, the Swedish Research,
402 the Swedish Physicians against AIDS Research Foundation, the Swedish International
403 Development Cooperation Agency, SIDASARC, VINNMER for Vinnova, Linköping
404 University Research Fund, CALF, and the Swedish Society of Medicine. V.V. is supported by
405 the Office of Research Infrastructure Programs(ORIP/NIH) base grant P51 OD011132 to
406 ENPRC. A.M. is supported by Grant No. 12020/04/2018-HR, Department of Health
407 Research, Government of India. The funders of this study had no role in the study design, data

408 collection, data analysis, data interpretation, or writing of the report. The authors thank the
409 Indian SARS CoV-2 Genomic Consortium (INSACOG), Department of Biotechnology,
410 Ministry of Science and Technology, Government of India for their approval and inclusion of
411 the State Public Health Laboratory (SPHL) as INSAGOG Genomic Sequencing Laboratory
412 (IGSL) vide File No: RAD/22017/28/2020/KGDDBT/Part (6) Dated 29th December 2021.

413

414 **Data Availability Statement**

415 The data that support the findings of this study are available from the corresponding author
416 upon reasonable request. The identified clinical data of patients in the study and the 'in-house'
417 bioinformatics pipeline in Python are available on request to the corresponding authors.

418

419 **Abbreviations**

420 ACE2, angiotensin-converting enzyme-2; CDC, Centers for Disease Control and Prevention;
421 cDNA, complementary DNA; COVID-19, coronavirus disease 2019; Ct, cycle threshold
422 value; FP, fusion peptide; HDU, high dependency unit; HR, heptad repeat; ICU, intensive care
423 unit; Polymerase Chain Reaction; NGS, next-generation sequencing; NTD, N-terminal
424 domain; QC, quality control; RBD, receptor binding domain; RMSD, root mean square
425 deviation; RT-PCR, Reverse transcription PCR; SARS-CoV-2, Severe Acute Respiratory
426 Syndrome Coronavirus 2; SD, spike subdomain; SP: signal peptide; SPHL, State Public Health
427 Laboratory; TE, Tris-EDTA; TM: Transmembrane domain; VOC, variants of concern; WGS,
428 whole genome sequencing.

429

430 **References**

- 431 1. **Zaidi AK, Singh RB.** SARS-CoV-2 variant biology and immune evasion. *Prog Mol Biol Transl Sci*
432 2024;202:45–66.
- 433 2. **Fan Y, Li X, Zhang L, Wan S, Zhang L, et al.** SARS-CoV-2 Omicron variant: recent progress and
434 future perspectives. *Signal Transduction and Targeted Therapy* 2022 7:1 2022;7:1–11.
- 435 3. **Chakraborty C, Bhattacharya M, Chopra H, Islam MA, Saikumar G, et al.** The SARS-CoV-2
436 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique
437 mutations, antibody evasion, and immune escape properties – an alarming global threat of a
438 surge in COVID-19 cases again? *Int J Surg* 2023;109:1041.
- 439 4. **Selvavinayagam ST, Yong YK, Joseph N, Hemashree K, Tan HY, et al.** Low SARS-CoV-2 viral
440 load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but
441 not with Omicron BA.1.1 and BA.2 variants. *Front Public Health* 2022;10:1018399.
- 442 5. **Mahilkar S, Agrawal S, Chaudhary S, Parikh S, Sonkar SC, et al.** SARS-CoV-2 variants: Impact
443 on biological and clinical outcome. *Front Med (Lausanne)*;9. Epub ahead of print 10 November
444 2022. DOI: 10.3389/FMED.2022.995960.
- 445 6. **Kumari M, Lu RM, Li MC, Huang JL, Hsu FF, et al.** A critical overview of current progress for
446 COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. *J Biomed*
447 *Sci*;29. Epub ahead of print 1 December 2022. DOI: 10.1186/S12929-022-00852-9.
- 448 7. **Lee D, Redfern O, Orengo C.** Predicting protein function from sequence and structure. *Nat Rev*
449 *Mol Cell Biol* 2007;8:995–1005.
- 450 8. **Pál C, Papp B, Lercher MJ.** An integrated view of protein evolution. *Nat Rev Genet* 2006;7:337–
451 348.

- 452 9. **Lomoio U, Puccio B, Tradigo G, Guzzi PH, Veltri P.** SARS-CoV-2 protein structure and sequence
453 mutations: Evolutionary analysis and effects on virus variants. *PLoS One* 2023;18:e0283400.
- 454 10. **Aksamentov I, Roemer C, Hodcroft E, Neher R.** Nextclade: clade assignment, mutation calling
455 and quality control for viral genomes. *J Open Source Softw* 2021;6:3773.
- 456 11. **Ravantti JJ, Martinez-Castillo A, Abrescia NGA.** Superimposition of Viral Protein Structures: A
457 Means to Decipher the Phylogenies of Viruses. *Viruses*;12. Epub ahead of print 1 October 2020.
458 DOI: 10.3390/V12101146.
- 459 12. **Carugo O, Pongor S.** A normalized root-mean-square distance for comparing protein three-
460 dimensional structures. *Protein Sci* 2001;10:1470.
- 461 13. **Davis JJ, Long SW, Christensen PA, Olsen RJ, Olson R, et al.** Analysis of the ARTIC Version 3
462 and Version 4 SARS-CoV-2 Primers and Their Impact on the Detection of the G142D Amino Acid
463 Substitution in the Spike Protein. *Microbiol Spectr*;9. Epub ahead of print 22 December 2021.
464 DOI: 10.1128/SPECTRUM.01803-21.
- 465 14. **Singh P, Sharma K, Singh P, Bhargava A, Negi SS, et al.** Genomic characterization unravelling
466 the causative role of SARS-CoV-2 Delta variant of lineage B.1.617.2 in 2nd wave of COVID-19
467 pandemic in Chhattisgarh, India. *Microb Pathog*;164. Epub ahead of print 1 March 2022. DOI:
468 10.1016/J.MICPATH.2022.105404.
- 469 15. **Selvavinayagam ST, Karishma SJ, Hemashree K, Yong YK, Suvaitenamudhan S, et al.** Clinical
470 characteristics and novel mutations of omicron subvariant XBB in Tamil Nadu, India - a cohort
471 study. *The Lancet regional health Southeast Asia*;19. Epub ahead of print 1 December 2023.
472 DOI: 10.1016/J.LANSEA.2023.100272.
- 473 16. **Selvavinayagam ST, Suvaitenamudhan S, Yong YK, Hemashree K, Rajeshkumar M, et al.**
474 Genomic surveillance of omicron B.1.1.529 SARS-CoV-2 and its variants between December
475 2021 and March 2023 in Tamil Nadu, India—A state-wide prospective longitudinal study. *J Med*
476 *Virol* 2024;96:e29456.
- 477 17. **Looi MK.** Covid-19: WHO adds JN.1 as new variant of interest. *BMJ* 2023;383:p2975.
- 478 18. **Planas D, Staropoli I, Michel V, Lemoine F, Donati F, et al.** Distinct evolution of SARS-CoV-2
479 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. *Nat*
480 *Commun*;15. Epub ahead of print 1 December 2024. DOI: 10.1038/S41467-024-46490-7.
- 481 19. **Wannigama DL, Amarasiri M, Phattharapornjaroen P, Hurst C, Modchang C, et al.**
482 Wastewater-based epidemiological surveillance of SARS-CoV-2 new variants BA.2.86 and
483 offspring JN.1 in south and Southeast Asia. *J Travel Med.* Epub ahead of print 4 March 2024.
484 DOI: 10.1093/JTM/TAAE040.
- 485 20. **Ou G, Yang Y, Zhang S, Niu S, Cai Q, et al.** Evolving immune evasion and transmissibility of
486 SARS-CoV-2: The emergence of JN.1 variant and its global impact. *Drug Discov Ther*;18. Epub
487 ahead of print 29 February 2024. DOI: 10.5582/DDT.2024.01008.
- 488 21. **Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Uriu K, et al.** Virological characteristics of the
489 SARS-CoV-2 JN.1 variant. *Lancet Infect Dis* 2024;24:e82.
- 490 22. **Wang Q, Iketani S, Li Z, Liu L, Guo Y, et al.** Alarming antibody evasion properties of rising
491 SARS-CoV-2 BQ and XBB subvariants. *Cell* 2023;186:279-286.e278.


- 492 23. **Patel N, Trost JF, Guebre-Xabier M, Zhou H, Norton J, et al.** XBB.1.5 spike protein COVID-19
493 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and
494 emerging XBB variants. *Scientific Reports* 2023 13:1 2023;13:1–11.
- 495 24. **Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Uriu K, et al.** Virological characteristics of the
496 SARS-CoV-2 JN.1 variant. *Lancet Infect Dis* 2024;24:e82.
- 497 25. **Uriu K, Ito J, Kosugi Y, Tanaka YL, Mugita Y, et al.** Transmissibility, infectivity, and immune
498 evasion of the SARS-CoV-2 BA.2.86 variant. *Lancet Infect Dis* 2023;23:e460–e461.
- 499 26. **Yang S, Yu Y, Xu Y, Jian F, Song W, et al.** Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under
500 heavy immune pressure. *Lancet Infect Dis* 2024;24:e70–e72.
- 501 27. **Karyakarte RP, Das R, Rajmane M V, Dudhate S, Agarasen J, et al.** Appearance and Prevalence
502 of JN.1 SARS-CoV-2 Variant in India and Its Clinical Profile in the State of Maharashtra. *Cureus*.
503 Epub ahead of print 22 March 2024. DOI: 10.7759/cureus.56718.
- 504 28. **Kosugi Y, Plianchaisuk A, Putri O, Uriu K, Kaku Y, et al.** Characteristics of the SARS-CoV-2
505 omicron HK.3 variant harbouring the FLip substitution. *Lancet Microbe*;0. Epub ahead of print
506 January 2024. DOI: 10.1016/s2666-5247(23)00373-7.
- 507 29. **Singh J, Pandit P, McArthur AG, Banerjee A, Mossman K.** Evolutionary trajectory of SARS-CoV-
508 2 and emerging variants. *Virology Journal* 2021 18:1 2021;18:1–21.
- 509 30. **Goga A, Bekker LG, Garrett N, Reddy T, Yende-Zuma N, et al.** Breakthrough SARS-CoV-2
510 infections during periods of delta and omicron predominance, South Africa. *The Lancet*
511 2022;400:269–271.
- 512 31. **Cantoni D, Murray MJ, Kalemra MD, Dicken SJ, Stejskal L, et al.** Evolutionary remodelling of
513 N-terminal domain loops fine-tunes SARS-CoV -2 spike . *EMBO Rep*;23. Epub ahead of print 6
514 October 2022. DOI: 10.15252/EMBR.202154322/SUPPL_FILE/EMBR202154322-SUP-0002-
515 DATASET1.XLSX.
- 516 32. **Haslwanter D, Dieterle ME, Wec AZ, O’Brien CM, Sakharkar M, et al.** A Combination of
517 Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the
518 Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. *mBio*;12. Epub ahead of print
519 1 October 2021. DOI: 10.1128/MBIO.02473-21.
- 520 33. **Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, et al.** Neutralizing and
521 protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-
522 2 spike protein. *Cell* 2021;184:2316-2331.e15.
- 523 34. **Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, et al.** SARS-CoV-2 variants, spike
524 mutations and immune escape. *Nat Rev Microbiol* 2021;19:409–424.
- 525 35. **Negi SS, Schein CH, Braun W.** Regional and temporal coordinated mutation patterns in SARS-
526 CoV-2 spike protein revealed by a clustering and network analysis. *Sci Rep*;12. Epub ahead of
527 print 1 December 2022. DOI: 10.1038/S41598-022-04950-4.
- 528 36. **Ravantti JJ, Martinez-Castillo A, Abrescia NGA.** Superimposition of Viral Protein Structures: A
529 Means to Decipher the Phylogenies of Viruses. *Viruses*;12. Epub ahead of print 1 October 2020.
530 DOI: 10.3390/V12101146.

- 531 37. **Bloom JD, Beichman AC, Neher RA, Harris K.** Evolution of the SARS-CoV-2 Mutational
532 Spectrum. *Mol Biol Evol*;40. Epub ahead of print 4 April 2023. DOI:
533 10.1093/MOLBEV/MSAD085.
- 534 38. **Dolan PT, Whitfield ZJ, Andino R.** Mapping the Evolutionary Potential of RNA Viruses. *Cell Host*
535 *Microbe* 2018;23:435–446.
- 536
537

538

539

FIGURES



540

541

FIGURE 1 A) Analysis of the proportions of different SARS-CoV-2 variants circulating in Tamil Nadu over time. The x-axis represents the timeline, the y-axis represents the proportion, and different colors represent distinct variants. B—H) Clinico-demographic characteristics, where B) median age, C) gender, D) symptoms, E) comorbidity, F) vaccination status, G) number of doses received, H) medical support, and I) Common symptoms among different age groups. Note: All patients recovered from COVID-19.

542


543

544

545

546


547



548
 549 **FIGURE 2** Amino acid changes in the different domains of JN.1 in comparison with *Wuhan-*
 550 *Hu-1*, BA.2, and XBB (Red colour indicates the unique mutations, the blue colour indicates
 551 the dynamic mutations, the black colour indicates random mutations and pale red indicates
 552 universal mutations). Fusion peptide (FP), Heptad Repeat (HR1/2), N-terminal domain (NTD),
 553 Receptor Binding Domain (RBD), Signal peptide (SP), Spike Subdomain (SD) and
 554 Transmembrane domain (TM) are the different motifs of the spike glycoprotein.

555

556



557


558 **FIGURE 3** The phylogenetic analysis of the JN.1 variant using a rooted tree and an unrooted
 559 tree illustrates the evolutionary relatedness among the sequences of JN.1 (n=66) compared
 560 with the reference genome of SARS-CoV-2 (*Wuhan-Hu-1*).

561

562

563

564



565

566

567

568

569

570

571

FIGURE 4 Superimposition of protein models. **A:** Superimposed protein model of *Wuhan Hu-1* reference model (red) with JN.1 specific mutations (blue). **B:** Superimposed protein model of JN.1 variant (green) with the study-specific unique mutation model identified in our study patients (red).

572 **Table 1: Unique and dynamic mutational pattern in spike protein among different lineages.**

573

| S.No | Comparison | Unique Mutations (n) | Unique Mutations | Dynamic Mutations (n) | Dynamic Mutations |
|------|--------------------------------------|----------------------|---|-----------------------|-------------------|
| 1 | JN.1 variants with <i>Wuhan-Hu-1</i> | 22 | T20L, P26Q, D53E, F55L, S60F, N81S, V83F, L84K, P85L, F86L, N87I, D88V, V90L, P174S, Q218L, A288S, V503A, P681R, M740I, S939F, V1104L, P1162L | 3 | P85K, V90Y, P681R |
| 2 | JN.1 variants with BA.2 | 14 | V83F, L84K, P85L, F86L, N87I, D88V, V90L, Y170E, Q218L, T307Q, T333R, F456L, Q506P, P507T | 2 | P85L, V90Y |
| 3 | JN.1 variants with XBB | 20 | A83V, L84K, P85K, F86L, N87I, D88V, V90L, F92V, Y170E, Q218L, T315V, S316C, F318I, N331K, T333R, N334S, T346R, F456L, Q506P, P507T | 3 | A83F, V90Y, T346I |

574

575

576

577

578
579

Table 2: Unique, dynamic, universal, and random mutations in the spike protein of JN.1 compared to the *Wuhan-Hu-1* sequence.

| UNIQUE MUTATION | | | | DYNAMIC MUTATION | | | UNIVERSAL MUTATION | | | RANDOM MUTATION | | | | |
|-----------------|-------|-------|---------|------------------|-----|-------|--------------------|-------|-------|-----------------|-------|-------|-------|---------|
| NTD | RBD | SD | HR1/HR2 | NTD | RBD | SD | NTD | RBD | SD | NTD | RBD | SD | FP | HR1/HR2 |
| V83F | V503A | P681R | S939F | P85K | - | P681H | G142D | N440K | D614G | T19I | G339H | N764K | D796Y | Q954H |
| L84K | - | M740I | V1104L | V90Y | - | - | T307Q | S477N | - | R21T | K356T | - | - | N969K |
| P85L | - | - | P1162L | - | - | - | - | N501Y | - | A27S | S371F | - | - | P1143L |
| F86L | - | - | - | - | - | - | - | - | - | S50L | S373P | - | - | - |
| N87I | - | - | - | - | - | - | - | - | - | V127F | S375F | - | - | - |
| D88V | - | - | - | - | - | - | - | - | - | F157S | T376A | - | - | - |
| V90L | - | - | - | - | - | - | - | - | - | R158G | R403K | - | - | - |
| Q218L | - | - | - | - | - | - | - | - | - | L212I | D405N | - | - | - |
| T20L | - | - | - | - | - | - | - | - | - | V213G | R408S | - | - | - |
| P26Q | - | - | - | - | - | - | - | - | - | L216F | K417N | - | - | - |
| D53E | - | - | - | - | - | - | - | - | - | H245N | V445H | - | - | - |
| F55L | - | - | - | - | - | - | - | - | - | A264D | G446S | - | - | - |
| S60F | - | - | - | - | - | - | - | - | - | - | N450D | - | - | - |
| N81S | - | - | - | - | - | - | - | - | - | - | L452W | - | - | - |
| P174S | - | - | - | - | - | - | - | - | - | - | L455S | - | - | - |
| A288S | - | - | - | - | - | - | - | - | - | - | N460K | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | T478K | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | N481K | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | E484K | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | F486P | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | Q498R | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | Y505H | - | - | - |

580
581

Table 3: Unique, dynamic, universal, and random mutations in the spike protein of JN.1 compared to the BA.2 sequence.

582

| UNIQUE MUTATION | | | | DYNAMIC MUTATION | | | UNIVERSAL MUTATION | | | RANDOM MUTATION | | | | |
|-----------------|-------|----|---------|------------------|-----|----|--------------------|-----|----|-----------------|-------|-------|-------|---------|
| NTD | RBD | SD | HR1/HR2 | NTD | RBD | SD | NTD | RBD | SD | NTD | RBD | SD | FP | HR1/HR2 |
| V83F | T33R | - | - | P85K | - | - | - | - | - | R21T | I332V | E554K | H681R | S939F |
| L84K | F456L | - | - | V90Y | - | - | - | - | - | A27S | G339H | A570V | - | P1143L |
| P85L | Q506P | - | - | - | - | - | - | - | - | S50L | R346T | P621S | - | - |
| F86L | P507T | - | - | - | - | - | - | - | - | V127F | K356T | - | - | - |
| N87I | - | - | - | - | - | - | - | - | - | F157S | S375F | - | - | - |
| D88V | - | - | - | - | - | - | - | - | - | R158G | T376A | - | - | - |
| V90L | - | - | - | - | - | - | - | - | - | L212I | R403K | - | - | - |
| Q218L | - | - | - | - | - | - | - | - | - | L216F | V445H | - | - | - |
| Y170E | - | - | - | - | - | - | - | - | - | H245N | G446S | - | - | - |
| T307Q | - | - | - | - | - | - | - | - | - | A264D | N450D | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | L452W | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | L455W | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | N460K | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | N481K | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | A484K | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | F486P | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | R493Q | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | H505Y | - | - | - |

583

584

585

586

587

588

589

590
591

Table 4: Unique, dynamic, universal, and random mutations in the spike protein of JN.1 compared to the XBB sequence.

| UNIQUE MUTATION | | | | DYNAMIC MUTATION | | | UNIVERSAL MUTATION | | | RANDOM MUTATION | | | | |
|-----------------|-------|----|---------|------------------|-------|----|--------------------|-----|----|-----------------|-------|-------|-------|---------|
| NTD | RBD | SD | HR1/HR2 | NTD | RBD | SD | NTD | RBD | SD | NTD | RBD | SD | FP | HR1/HR2 |
| A83V | N331K | - | - | A83F | T346I | - | - | - | - | R21T | I332V | E554K | H681R | S939F |
| L84K | T333R | - | - | V90Y | - | - | - | - | - | A27S | K356T | A570V | - | P1143L |
| P85K | N334S | - | - | - | - | - | - | - | - | S50L | I368L | P621S | - | - |
| F86L | T346R | - | - | - | - | - | - | - | - | V127F | R403K | - | - | - |
| N87I | F456L | - | - | - | - | - | - | - | - | Q146H | P445H | - | - | - |
| D88V | Q506P | - | - | - | - | - | - | - | - | F157S | N450D | - | - | - |
| V90L | P507T | - | - | - | - | - | - | - | - | R158G | L452W | - | - | - |
| F92V | - | - | - | - | - | - | - | - | - | E183Q | L455W | - | - | - |
| Y170E | - | - | - | - | - | - | - | - | - | L212I | N460K | - | - | - |
| Q218L | - | - | - | - | - | - | - | - | - | E213G | N481K | - | - | - |
| T315V | - | - | - | - | - | - | - | - | - | L216F | A484K | - | - | - |
| S316C | - | - | - | - | - | - | - | - | - | H245N | S486P | - | - | - |
| F318I | - | - | - | - | - | - | - | - | - | A264D | S490F | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | H505Y | - | - | - |

592
593

Table 5: List of mutations observed in our strains and previously reported JN.1 variants.


| S. no | Mutations | Motif | Subunit |
|--------------|------------------|--------------|----------------|
| 1 | R21T | NTD | S1 |
| 2 | S50L | NTD | |
| 3 | V127F | NTD | |
| 4 | F157S | NTD | |
| 5 | R158G | NTD | |
| 6 | L216F | NTD | |
| 7 | H245N | NTD | |
| 8 | A270D | NTD | |
| 9 | I332V | RBD | |
| 10 | K356T | RBD | |
| 11 | R403K | RBD | |
| 12 | N450D | RBD | |
| 13 | L455S | RBD | |
| 14 | N481K | RBD | |
| 15 | E554K | SD1/2 | |
| 16 | A570V | SD1/2 | |
| 17 | P621S | SD1/2 | |
| 18 | S939F | HR1 | S2 |
| 19 | P1143L | HR2 | |

Table 6: List of mutations observed in a few lineages/sub-lineages but not in our study.


| S. No | Mutations | Motif | Variants bearing the mutation |
|--------------|------------------|--------------|--------------------------------------|
| 1. | L24S | NTD | BA.2; BA.2.75; BA.2.10; BA.4; BA.5 |
| 2. | A67V | NTD | BA.1 |
| 3. | H146Q | NTD | XBB.1 |
| 4. | K147E | NTD | BA.2.75 |
| 5. | W152R | NTD | BA.2.75 |
| 6. | F157L | NTD | BA.2.75 |
| 7. | Q183E | NTD | XBB1 |
| 8. | I210V | NTD | BA.2.75 |
| 9. | L212V | NTD | BA.1 |
| 10. | R214K | NTD | BA.1 |
| 11. | G252V | NTD | BA.1 |
| 12. | G257S | NTD | BA.2.75 |
| 13. | L368I | RBD | XBB1 |
| 14. | Y449S | RBD | BA.1 |
| 15. | F490L | RBD | BA.1 |
| 16. | Q493R | RBD | BA.2;BA.1.1.529;BA2.10 |
| 17. | G496N | RBD | BA.1 |
| 18. | T500A | RBD | BA.1 |
| 19. | G502S | RBD | XBB1 |
| 20. | N658S | SD1/2 | BA.4 |
| 21. | Q755R | SD1/2-FP | BA.2.75 |
| 22. | D950N | HR1 | BA.1.617.2 |
| 23. | L981F | HR1 | BA.1 |
| 24. | S982A | HR1 | BA.1.1 |
| 25. | V1228L | TM | BA.1 |

A


Comparison of JN.1 variant with Wuhan-Hu-1


S1 Subunit
S2 Subunit
Spike Glycoprotein**B**


Comparison of JN.1 variant with BA.2

S1 Subunit
S2 Subunit
Spike Glycoprotein**C**

Comparison of JN.1 variant with XBB

S1 Subunit
S2 Subunit
Spike Glycoprotein



A**B**